3,003,064 Shares in Boston Scientific Co. (BSX) Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,003,064 shares of the medical equipment provider’s stock, valued at approximately $115,618,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BSX. FMR LLC raised its position in Boston Scientific by 10.4% during the 2nd quarter. FMR LLC now owns 156,622,452 shares of the medical equipment provider’s stock valued at $5,121,554,000 after purchasing an additional 14,711,069 shares during the last quarter. Morgan Stanley raised its position in Boston Scientific by 114.6% during the 2nd quarter. Morgan Stanley now owns 7,517,384 shares of the medical equipment provider’s stock valued at $245,818,000 after purchasing an additional 4,013,765 shares during the last quarter. Epoch Investment Partners Inc. bought a new position in Boston Scientific during the 2nd quarter valued at approximately $116,062,000. BlackRock Inc. raised its position in Boston Scientific by 2.9% during the 2nd quarter. BlackRock Inc. now owns 109,355,395 shares of the medical equipment provider’s stock valued at $3,575,920,000 after purchasing an additional 3,062,924 shares during the last quarter. Finally, TD Asset Management Inc. raised its position in Boston Scientific by 531.8% during the 2nd quarter. TD Asset Management Inc. now owns 2,488,256 shares of the medical equipment provider’s stock valued at $81,366,000 after purchasing an additional 2,094,436 shares during the last quarter. 91.00% of the stock is owned by institutional investors and hedge funds.

BSX stock opened at $35.38 on Tuesday. Boston Scientific Co. has a fifty-two week low of $24.54 and a fifty-two week high of $39.44. The company has a current ratio of 0.83, a quick ratio of 0.60 and a debt-to-equity ratio of 0.62. The company has a market cap of $49.55 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 2.35 and a beta of 0.59.



Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.01. Boston Scientific had a return on equity of 27.38% and a net margin of 6.93%. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.40 billion. During the same quarter in the prior year, the business earned $0.31 EPS. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. On average, analysts expect that Boston Scientific Co. will post 1.39 EPS for the current year.

BSX has been the subject of a number of recent analyst reports. Raymond James upped their price target on Boston Scientific from $40.00 to $41.00 and gave the company a “strong-buy” rating in a research report on Tuesday, September 4th. Piper Jaffray Companies upped their price target on Boston Scientific to $38.00 and gave the company an “overweight” rating in a research report on Thursday, July 26th. Morgan Stanley upped their price target on Boston Scientific from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, July 26th. Jefferies Financial Group raised Boston Scientific from a “hold” rating to a “buy” rating and upped their price target for the company from $34.00 to $42.00 in a research report on Tuesday, September 4th. Finally, Royal Bank of Canada upped their price target on Boston Scientific to $36.00 and gave the company a “top pick” rating in a research report on Monday, July 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $39.00.

In related news, Chairman Michael F. Mahoney sold 116,666 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $35.88, for a total value of $4,185,976.08. Following the sale, the chairman now owns 2,023,104 shares in the company, valued at approximately $72,588,971.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $38.80, for a total value of $194,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 295,834 shares of company stock worth $11,038,468 in the last quarter. Company insiders own 0.73% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Story: S&P 500 Index

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply